Page last updated: 2024-08-17

quinoxalines and sorafenib

quinoxalines has been researched along with sorafenib in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's4 (80.00)2.80

Authors

AuthorsStudies
Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S1
Capelletti, MM; Manceau, H; Peoc'h, K; Puy, H1
Alanazi, MM; Alanazi, WA; Alasmari, AF; Albassam, H; Alsaif, NA; Elwan, A; Mahdy, HA; Obaidullah, AJ; Taghour, MS1
Al-Hossaini, AM; Al-Mehizi, AA; Alanazi, MM; Alkahtani, HM; Alsaif, NA; Elwan, A; Mahdy, HA; Obaidullah, AJ; Taghour, MS1
Abulkhair, HS; Eissa, IH; El-Adl, K; Mehany, ABM; Sakr, HM; Yousef, RG1

Reviews

1 review(s) available for quinoxalines and sorafenib

ArticleYear
Ferroptosis in Liver Diseases: An Overview.
    International journal of molecular sciences, 2020, Jul-11, Volume: 21, Issue:14

    Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cysteine; Ferroptosis; Glutathione; Heme; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Lipoxygenase; Liver Diseases; Liver Neoplasms; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction; Sorafenib; Spiro Compounds; Sulfasalazine; Tumor Suppressor Protein p53

2020

Other Studies

4 other study(ies) available for quinoxalines and sorafenib

ArticleYear
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Molecular diversity, 2022, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2022
Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
    Archiv der Pharmazie, 2022, Volume: 355, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Female; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Mice; Quinoxalines; Rats; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2

2022
New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies.
    Archiv der Pharmazie, 2022, Volume: 355, Issue:7

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Proliferation; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinoxalines; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2022